Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 100.50p 100.00p 101.00p 100.50p 100.50p 100.50p 2,992 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.9 -29.3 -56.0 - 48.96

Midatech Pharma Share Discussion Threads

Showing 226 to 250 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
26/7/2017
08:36
Positive update this AM. Monetisation some way off but looking good. Perhaps one more good bit of news in the next couple of months and we will see a re-rating.
gwatson56
21/7/2017
10:40
I agree, news is needed. Perhaps the price / lack of trades is getting to a point where a bid is considered. Reading what has been released all seems positive to me, the last presentation was very detailed. Maybe the time for a top up, contrarian view 'n all.
gwatson56
20/7/2017
12:46
Numbers at moment are almost irrelevant need good trial news/progress on core platforms
luffness
20/7/2017
06:22
News flow seems positive - but the RNS on 18 July: "The Board expects total gross revenues of approximately £5.2 million, a 37% increase from the £3.8 million recorded in the six months to June 2016, and the Company remains on-track to deliver market expectations for the full year 2017. Sales for the second half of 2016 represented 59% of full year gross revenues and the Board anticipates a similar split in 2017, subject to continued sales growth at approximately the H1 2017 vs. H1 2016 rate." was met with a flurry of selling. While the numbers of trades, and shares were quite low, it looks to me (from the LSE site) as though all except one trade this week is marked as a sell. At least the MM's aren't pushing the price down hard - is that enough to conclude that the MM's aren't negative about the company? Why the selling? Is it just people getting bored and moving on because the numbers are merely good, and not astronomically spectacular?
edrifter
13/6/2017
09:42
I see from the RNS that only sell-side analysts were invited!
ih_433513
13/6/2017
09:20
Need a few such reports to get things moving again. Good newsflow though.
hutch_pod
13/6/2017
08:53
R&D Day for analysts and institutions in Bilbao today. Can we hope for some positive reports?
ih_433513
07/6/2017
07:15
Novartis deal
gersemi
28/5/2017
10:21
Bit of interest in the stock in the US on Friday.
ih_433513
19/5/2017
10:37
Anyone go?
jamtomorrow2
17/5/2017
07:42
If anyone goes please ask Jim Phillips whether they have hit bioequivalence on Q-Octreo.
jamtomorrow2
15/5/2017
09:09
Midatech CEO Jim Phillips will be presenting to investors at the Proactive One2One Forum on Thursday 18th May. For details and registration click here: https://tinyurl.com/lbg2ggd
aim_trader
13/4/2017
21:03
200K of trades reported late on .... looks like trades were split over the past 3 days. Todays looks a buy the others I reckon were also buys (at a good price).. Bought a good few at 112.75 this week as I reckoned we are due a rise as the results and podcast were not that bad and even the product that was written down is still being sold (not that I understood this bit). Edit 19/4 Is someone accumulating here ?, some large parcels of shares traded of late ... Edit 5/5 Over a million in one trade (thats 2% of the co) at 118p early doors. We might have a holding RNS at this rate.
gwatson56
07/4/2017
09:34
Listening to the recent podcast on Midatech's website, Dr Jim reckons there'll be progress towards profitability this year. More patience required, maybe.
investopia
05/4/2017
22:00
Pipeline - the Q-Octreotide drug needs to be accepted as a biosimilar otherwise long trials - the child cancer technique has only treated 4 children in a year (GWPH has trialled way more than that for the same condition and the live polio method has tested hundreds in that time) - and the liver cancer drug is very early stage. So I'm not buying the big progress story - quite the contrary. The US company turning over £6m - big deal. The old management were forecasting $20m based on the CVR.
jamtomorrow2
05/4/2017
21:28
Well..revenues and pipeline look good and raised a bunch of cash.
hutch_pod
05/4/2017
13:57
Loss of £20m and one failed drug and a share price down 50%. A really great year!
jamtomorrow2
05/4/2017
09:28
Upbeat message from Jim Phillips on Proactive Investors .... video and commentary...
gwatson56
10/3/2017
07:34
Good news...Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
pickledcabbage
21/1/2017
20:51
Panmure reiterate target of 297p and N+1 Singer 283p. You pays yer money and takes yer chance.
deltrotter
21/1/2017
13:23
Weekly view - the triple share purchase is code for its on the turn. The multi strategy blurb prob means the one that's doing well isn't the one your expecting. Still, he's saying something is selling well. Williams looks LT bowly & poss some inst bites on the volume in anticipation of swinging to profit. Don't how long that is so maybe a longer term play - but CEO & Panmure are dropping hints - poss to inst buyers too who may fancy it here (half IPO) or adjusting their avg entry weight. The tallest volume spikes look like an inst trader trying to nail the btm. The technical damage of the 3 long black bars needs to be repaired at some point (ie go back to the green line). A B/O will confirm.
luckymouse
20/1/2017
11:43
I sold this morning. This announcement was nothing new and the price will drift back if they have no other news.
martinwj
20/1/2017
11:21
n an analyst rating update on Friday shares of Midatech Pharma Plc (LON:MTPH) had their rating reiterated by analysts at Panmure Gordon. The broker said it has now set a ‘Buy’ rating on shares of Midatech Pharma Plc with a price target of 297.
deltrotter
20/1/2017
11:20
Sorry double post.
jamtomorrow2
20/1/2017
11:20
Double digit sales growth in US based Dara in 2017. Big deal eh! You'd get more than that just on the exchange rate difference. This company has had no good news since the IPO. About time one of their many R&D projects showed some promise. What about the two child patients in the brain cancer trial? Not a mention of their progress. Surely if they were making good progress then every hospital around the world would be requesting a similar trial on their patients. But not a word. Everything is SO slow.
jamtomorrow2
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170822 13:12:24